Related Experiment Videos
Metabolic manifestations of low-dose diuretics
1Orange County Heart Institute and Research Center, Orange, California 92868, USA.
Insights
Hypertension is a complex syndrome involving multiple cardiovascular risk factors, not just high blood pressure. Low-dose hydrochlorothiazide effectively reduces blood pressure with minimal metabolic side effects.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Hypertension management focusing solely on blood pressure has not reduced coronary artery disease.
- Hypertension is a complex inherited syndrome of linked cardiovascular risk factors.
- These factors include lipid abnormalities, insulin resistance, renal dysfunction, left ventricular hypertrophy, and reduced arterial compliance.
Purpose of the Study:
- To re-evaluate the role of diuretics in hypertension management.
- To assess the metabolic side effects of low-dose hydrochlorothiazide.
- To determine the efficacy of low-dose hydrochlorothiazide in blood pressure reduction.
Main Methods:
- Review of recent data on hypertension and cardiovascular disease outcomes.
- Analysis of the impact of different antihypertensive drug classes on metabolic risk factors.
- Evaluation of low-dose hydrochlorothiazide's efficacy and safety.
Main Results:
- High-dose diuretics and beta-blockers negatively affect lipid metabolism and insulin sensitivity.
- Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists have a neutral metabolic effect.
- Low-dose hydrochlorothiazide (6.25-12.5 mg) significantly reduces blood pressure with minimal metabolic side effects.
Conclusions:
- Hypertension management should address all contributing cardiovascular risk factors.
- Low-dose hydrochlorothiazide is a safe and effective option for hypertension treatment.
- Hydrochlorothiazide at low doses can be used as monotherapy or in combination therapy.
Abstract:
Hypertension has been defined and treated as a disease of abnormal systolic and diastolic blood pressure. Recent data have, however, demonstrated that effective blood-pressure control has not resulted in the expected decrease in coronary artery disease. These findings are probably a result of hypertension being a complex inherited syndrome of cardiovascular risk factors, all of which are genetically linked and all of which contribute to the development of cardiovascular disease in these patients. Included in the hypertension syndrome are abnormalities of lipid profile, insulin resistance, changes in renal function, left ventricular hypertrophy and reduced arterial compliance. In many patients, high blood pressure is a late manifestation of this disease process. Since all cardiovascular risk factors contribute to heart disease in these patients, they should all be considered in the management of this disease process. Diuretics and beta blockers, when used at high doses, negatively impact lipid metabolism and insulin sensitivity, while angiotensin converting enzyme (ACE) inhibitors and calcium antagonists tend to have a neutral effect on these metabolic risk factors. These findings have resulted in decreased use of diuretics and beta blockers in favor of newer agents such as ACE inhibitors and calcium antagonists. However, recent data have demonstrated that when used at low doses (6.25 or 12.5 mg of hydrochlorothiazide), diuretics lack significant metabolic side effects while bringing about significant reductions in blood pressure. Thus, at these doses, hydrochlorothiazide is a useful drug in the treatment of hypertension, both as monotherapy and in combination therapy.